07/07/2026 11:20 – Other information

Revenue generated from Qelo users increased from EUR 110.84 thousand in the first half of 2025 to EUR 227.35 thousand in the same period of 2026, which represents an increase of 105 percent . At the time of publishing this report, the Company is changing its revenue expectations from the range of €1.1 million to €1.5 million and increasing them to the range of €1.2 million to €1.6 million.

Download document

06/30/2026 14:13 – Other information

In 2025, the company enasolAuto doo under the commercial trademark Qelo achieved significant revenue growth. At the end of the year, the audited revenues of the Company amounted to EUR 562,797.00, which is a 176% increase compared to 2024, when the revenues were EUR 203,362.00.

Download document

06/15/2026 13:52 – Other information

enasolAuto d.o.o. has established the company Qelo Imovina d.o.o. which is 100% owned by enasolAuto d.o.o.. The purpose of establishing the company is to be an SPV through which CAPEX will be financed for the construction of the Qelo charging network in the future period.

Download document

05/18/2026 11:45 – Other information

Glucodent has signed a clinical study agreement with KB Vuk Vrhovec, The University of Zagreb School of Dental Medicine, and now also with the laboratory within KBC Rebro Zagreb. This agreement enables the obtaining of approvals for conducting the clinical study in which the medical device will be tested.

Download document

04/29/2026 15:39 – Other information

The first quarter of 2026 was a record for the number of fillings and revenues for the first quarter of the year. At this time, the Company remains committed to its revenue projection for 2026. In 2026, the Company expects revenues in the range of €1.1 million – €1.5 million. This means an increase in revenue of 2 to 2.6 times higher than the previous business year.

Download document

03/31/2026 16:04 – Inside information

enasolAuto d.o.o., as the owner of the Qelo brand and electric vehicle charging system, hereby informs the market that a process has been initiated for the sale of a 10% ownership stake in enasolAuto d.o.o. An existing shareholder (Enasol d.o.o.) is selling its 10% stake to a special purpose vehicle (SPV – Qorex One d.o.o.).

Download document

03/10/2026 14:30 – Other information

enasolAuto has changed its business residence. The new adress is: enasolAuto d.o.o. Selska cesta 136 10000 Zagreb Republika Hrvatska

Download document

02/23/2026 07:44 – Other information

Business results in 2025. and guidance for2026.

Download document

07/28/2025 08:45 – Inside information

Glucodent Ltd. has, through the company Maiwald GmbH, submitted its second patent application to the European Patent Office in order to protect its intellectual property. By submitting this second patent application, the prerequisites for the next phase of product development—clinical trials—have been established.

Download document

05/13/2025 12:01 – Other information

"GLUCODENT d.o.o., hereby notifies that on May 9, 2025, an increase in the Company’s share capital was registered in the court register of the Commercial Court in Zagreb — from the amount of EUR 7,590.00, by an amount of EUR 410.00, to a total of EUR 8,000.00, fully paid in cash.

Download document

04/04/2025 14:19 – Inside information

Glucodent Ltd, through the company Maiwald GmbH, has submitted a patent application to the European Patent Office to protect its intellectual property for a synthesized molecule that forms the foundation of Glucodent’s future medical product.

Download document

10/15/2024 13:24 – Inside information

Glucodent Ltd. has successfully completed the examination of the effect of the API on the growth and development (proliferation) of pathogenic bacteria in the oral cavity with positive results.

Download document

09/23/2024 11:14 – Inside information

Glucodent Ltd. has successfully completed the examination of the effect of the API on the pH of artificial saliva. The results obtained show that the action of the API exceeds the initial goals set by the scientists involved in the development of the GLUCODENT© product.

Download document

07/31/2024 12:42 – Inside information

Glucodent Ltd. and IQVIA have signed an agreement to develop a "Data Informed Protocol Assessment" for an oral pathology product in diabetics

Download document

07/15/2024 16:29 – Inside information

Glucodent Ltd. has successfully synthesized various APIs to form the basis for further research on the medical product for treating oral pathology in diabetics.

Download document